EGI
XENE icon

EAM Global Investors’s Xenon Pharmaceuticals XENE Stock Holding History

EAM Global Investors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-146,387
Closed -$5.77M – 200
2022
Q4 		$5.77M Sell
146,387
-8,098
-5% -$295K 1.49% 4
2022
Q3 		$5.58M Buy
154,485
+3,996
+3% +$144K 1.48% 4
2022
Q2 		$4.58M Buy
+150,489
New +$4.55M 1.12% 12

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

EAM Global Investors's XENE Position: Q1 2023 in Review

EAM Global Investors sold out of Xenon Pharmaceuticals (XENE) in Q1 2023, closing a stake of 146,387 shares — an estimated $5.77M sold.

EAM Global Investors first reported a position in XENE in Q2 2022 and held it in 3 quarters. The position peaked at $5.77M in Q4 2022. 163 funds tracked by Wall St. Rank hold XENE as of Q1 2023.

  • EAM Global Investors reported no remaining Xenon Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • EAM Global Investors sold 146,387 Xenon Pharmaceuticals shares in Q1 2023, an estimated $5.77M.
  • EAM Global Investors first reported a position in Xenon Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • EAM Global Investors's Xenon Pharmaceuticals position peaked at $5.77M in Q4 2022.
  • 163 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2023.

Based on EAM Global Investors's 13F filing for Q1 2023, filed 15 May 2023.